Alnylam Announces Interim Phase 1 Data of Nucresiran (Aln-Ttrsc04) Showing Rapid Knockdown of Ttr That Is Sustained at Six Months Following a Single Dose
Alnylam宣佈核瑞尼蘭(Aln-Ttrsc04)第一階段中期數據顯示,Ttr快速減少,在單劑量後持續六個月
Alnylam Announces Interim Phase 1 Data of Nucresiran (Aln-Ttrsc04) Showing Rapid Knockdown of Ttr That Is Sustained at Six Months Following a Single Dose
Alnylam宣佈核瑞尼蘭(Aln-Ttrsc04)第一階段中期數據顯示,Ttr快速減少,在單劑量後持續六個月
使用瀏覽器的分享功能,分享給你的好友吧